Everything you need to know about HRT

Download Report

Transcript Everything you need to know about HRT

EVERYTHING YOU NEED TO
KNOW ABOUT HRT
Urvi Vyas
MENOPAUSE
The last menstrual period
 >12 months amennorhoea with no other cause in
women >50 years
 Occurs earlier in smokers
 High production of FSH and LH as the negative
feedback from oestrogen diminishes

CLINICAL FEATURES
Vasomotor- hot flushes
 Urogenital- vaginal dryness and atrophy,
recurrent UTI’s and incontinence
 Psychological- irritability, confusion, loss of
libido, depression
 CVS- increased risk of ischaemic heart disease
 Osteoporosis- decreased bone density

MANAGEMENT
Oral tablets- oestrogen only, opposed oestrogen,
continuous combined oestrogen and progesterone
therapy
 Patches
 Creams
 implants

INDICATIONS FOR HRT
Early menopause, continue until age 50
 Hysterectomy before the menopause, even if the
ovaries are conserved
 Relief of symptoms during the menopause
 2nd line treatment of osteoporosis for women >51
years

CHOICE OF PREPARATION
For women without a uterus i.e had
hysterectomy- give oestrogen alone
Premarin, Progynova, Harmogen
 For women with an intact uterus- progesterone is
required for the last 12-14 days of the cycle to
prevent endometrial proliferation
Prempack, Nuvelle, Trisequens
 Continuous combined oestrogen and progesterone
therapyKliofem, Premique, Climesse

CONTRAINDICATIONS
Oestrogen-dependent cancer i.e. endometrial
cancer
 History of breast cancer
 Active or recent arterial thromboembolic disease
(angina or MI)
 VTE
 Liver disease
 Dubin-Johnson and Rotor syndromes

EVIDENCE REGARDING RISKS
The womens health initiative (WHI) (JAMA
2002;288;321) RCT of 16000 asymptomatic post
menopausal women aged 50-79, randomised to
continuous combined HRT or placebo.
 A small increase in the rates of
breast cancer (from 30 to 38)
coronary heart disease (from 30 to 37)
stroke (from 21 to 29)
VTE (from 16 to 34)

A decrease in
colorectal cancer (from 16 to 10)
hip fractures (from 15 to 10)
 Overall global risk was 15% higher in the HRT
group
 Compounding factors were that the average age
was 63, older than the UK average, and
continuous combined HRT rather than cyclical
HRT was used

THE MILLION WOMEN STUDY
Epidemiological cohort study looking at women’s
HRT use when invited for breast screening, and
then followed up to look at breast cancer
development (Lancet 2003;362:419)
 All women on HRT had a higher breast cancer
risk than never users
 The risk was highest with combined preparations
 The absolute risk remains small eg for 1 000
women taking combined HRT for 5 years there
would be 6 extra cases of breast cancer

Oestrogen-only HRT and tibolone are associated
with small increases in endometrial cancer
 Combined HRT decreases endometrial cancer
risk
 But combined HRT is associated with a greater
increase in breast cancer risk than oestrogenonly or tibolone
 Because breast cancer is more common, overall
there is greater overall risk of cancer with
combined HRT

HRT AND BREAST CANCER RISK
Your pt aged 50, has a 6.1% risk of getting breast
cancer in the next 30 year.
 If she takes combined HRT for 3 years the risk
rises to 6.41%
 For 5 years, to 6.7%
 For 10 years, to 7.69%
 With oestrogen only HRT, after 5 year the risk is
6.28%
(BMJ 2005:331:347)


The risk/benefit ratio is favourable to treat
menopausal symptoms, in fully-informed women,
using the lowest possible doses for the shortest
possible time
WHEN LONG TERM HRT NEEDED
Long term combined preparations are less safe
than oestrogen alone
 Consider using oestrogen alone with an IUS
 Consider Tibolone

TIBOLONE
1st line treatment for menopausal sx
 2nd line therapy for prevention of osteoporosis
 2.2 times inc risk of stroke
 Inc risk of endometrial cancer, risk increases
with duration of use
 Increased risk of having breast cancer diagnosed,
lower than for combined HRT, risk returned to
baseline within a few years of stopping treatment
 Decreases HDL

TOPICAL CREAMS
Deliver oestrogen locally to vaginal tissues:
pessaries, creams, rings
 No progesterone is needed but use is limited to 3
months if uterus is present

ALTERNATIVES
Clonidine may reduce flushing symptoms but has
many side effects
 Beta-blockers may be used for palpitations and
tachycardia
 Antidepressants and sedatives can be used if
symptoms persist
 Calcium, vitamin D, Bisphosphonates for
osteoporosis

COMPLEMENTARY TREATMENTS
Black cohosh-seems to ease hot flushes but long
term effects are unknown
 Red Clover-conflicting evidence, some species
contain coumarins so unsuitable for women who
take anticoagulants such as warfarin
 Dong quai, evening primrose oil, vitamin E and
ginseng are no better than placebo
 Kava has been linked to cases of serious liver
damage and so should be avoided
